Ameritrade's new forthcoming tool, which unfortunately seem to come from Medved rather than Spooz, rather touts it backtesting capability. That's what I'm told here on the boards and from Ameritrade. The point being: no seeming Ameritrade deal, unless we get a huge surprise.
Medved's lowest level has always been free, yes, but you can pay for higher levels. Medved has on its own touted its backtesting capabilties, though I'm not sure what level you need to get that. It is a little bit of falsification to say the Medved "is free". And anyway, the point is we see a new tool available on Ameritrade, and if previews and opinions are correct, which I admit they may not be, it has absolutely nothing to do at all with Spooz, despite the CEO's statement that the "Ameritrade deal is well-known", without any further detail, or followup, or PRs.
News 
Market Data 
Discover 
AI
